Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to stop rare lymphoma from coming back

NCT ID NCT07414758

Recruiting now Disease control Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether the drug golidocitinib can help people with peripheral T-cell lymphoma (PTCL) stay in remission longer after their first round of chemotherapy. About 136 patients who responded to chemo will receive either golidocitinib or a placebo pill every other day for up to 2 years. The main goal is to see if the drug delays disease progression or death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
golidocitinib
What this could lead to
If successful, this could provide a new maintenance option to delay lymphoma progression after initial chemotherapy.
What could go wrong
This is a relatively small Phase 3 trial (68 per arm), and the drug may not improve survival or could cause side effects. Results may not apply to all PTCL subtypes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERIPHERAL T CELL LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai General hospital,Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200080, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.